Cargando…
ALK阳性非小细胞肺癌靶向治疗耐药机制及预后标志物的研究进展
Echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) fusion accounts for 3%-5% of non-small cell lung cancer (NSCLC) patients. With the in-depth study of the EML4-ALK driver gene, ALK inhibitors represented by crizotinib have been gradually developed and applied in...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679215/ https://www.ncbi.nlm.nih.gov/pubmed/33203201 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.44 |